NUTEK OIDO
Redefining precision in Surgical Oncology, on-the-body cancer tissue detection, during operation
Company Overview
Snapshot
Founded in June 2019 by Dov Cohen, Ofer Braun, and Prof. MD. Hanoch Kashtan, NUTEK OIDO operates with 1–10 employees. The company has raised $1.78M across 6 funding rounds. In March 2023, NUTEK OIDO received a grant from the FFG - Austrian Federal Innovation Authority to support its research and development efforts.
Business overview
NUTEK OIDO is a Health Tech & Life Sciences company focused on pioneering precision in Surgical Oncology. The company develops the "Rainbow Probe," a high-resolution hyperspectral imaging handheld device designed to detect residual cancer tissues on a patient's body during surgery. This technology aims to prevent cancer recurrence and repeated operations by guiding surgeons to the exact location of undetected cancer tissue for immediate removal. Its initial application is in Breast Cancer, with plans for expansion into other high-precision and minimally invasive cancer surgical interventions. NUTEK OIDO operates in the medical devices sector, serving hospitals, healthcare organizations, and insurance companies globally.
Strategic signal
In July 2024, NUTEK OIDO was highlighted for its innovative use of space technology to identify remaining cancer cells during surgery. This signals a significant advancement in real-time cancer diagnosis, demonstrating the company's ability to leverage cutting-edge technology for critical medical applications and potentially reducing cancer recurrence rates.
Log in to access full profile ›Company Intelligence Q&A
- What is NUTEK OIDO's core product?
- NUTEK OIDO's core product is the "Rainbow Probe," a high-resolution hyperspectral imaging handheld device used by surgeons to scan the operation cavity during surgery to detect and locate remaining cancer tissue.
- When was NUTEK OIDO founded and by whom?
- NUTEK OIDO was founded in June 2019 by Dov Cohen, Ofer Braun, and Prof. MD. Hanoch Kashtan.
- What was a notable achievement for NUTEK OIDO in December 2020?
- In December 2020, NUTEK OIDO received a grant from the Merage Institute after winning the '45+ Entrepreneurs' Competition'.
- What is the primary application of NUTEK OIDO's technology?
- NUTEK OIDO's initial application for its Rainbow Probe technology is in breast cancer, with plans to expand to other high-precision and minimally invasive cancer surgical interventions.